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Abstract
It is now widely accepted in the field that the normally secreted chaperone clusterin is redirected to the cytosol during
endoplasmic reticulum (ER) stress, although the physiological function(s) of this physical relocation remain unknown.
We have examined in this study whether or not increased expression of clusterin is able to protect neuronal cells
against intracellular protein aggregation and cytotoxicity, characteristics that are strongly implicated in a range of
neurodegenerative diseases. We used the amyotrophic lateral sclerosis-associated protein TDP-43 as a primary model to
investigate the effects of clusterin on protein aggregation and neurotoxicity in complementary in vitro, neuronal cell
and Drosophila systems. We have shown that clusterin directly interacts with TDP-43 in vitro and potently inhibits its
aggregation, and observed that in ER stressed neuronal cells, clusterin co-localized with TDP-43 and specifically reduced
the numbers of cytoplasmic inclusions. We further showed that the expression of TDP-43 in transgenic Drosophila
neurons induced ER stress and that co-expression of clusterin resulted in a dramatic clearance of mislocalized TDP-43
from motor neuron axons, partially rescued locomotor activity and significantly extended lifespan. We also showed that
in Drosophila photoreceptor cells, clusterin co-expression gave ER stress-dependent protection against proteotoxicity
arising from both Huntingtin-Q128 and mutant (R406W) human tau. We therefore conclude that increased expression
of clusterin can provide an important defense against intracellular proteotoxicity under conditions that mimic specific
features of neurodegenerative disease.
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Introduction
Protein misfolding, aggregation and deposition are unify-
ing features of a wide range of neurodegenerative dis-
eases [1]. The ability of neurons to manage the burden
of misfolded proteins and to resist their accumulation
into insoluble protein deposits depends critically on the
functioning of molecular chaperones. Previous studies
have demonstrated that elevation of chaperone levels
can protect against neurotoxicity resulting from the effects
of pathological protein misfolding in cell culture and in
transgenic animal models [2, 3]. Most chaperones are
localised within intracellular compartments, although some
are secreted into the extracellular environment. Prominent
amongst such extracellular chaperones is clusterin (CLU),
which is present in both plasma and cerebrospinal fluid
(CSF). CLU is a cytoprotective chaperone whose expres-
sion level is increased in response to a diverse range of
stresses including heat, pro-apoptotic insults, oxidative
stress, ionising radiation, and proteotoxicity [4–6]. It has
been linked to a correspondingly diverse group of clinical
disorders associated with protein misfolding including
Alzheimer’s disease (AD) [7], amyloidotic cardiomyopathy
[8] and familial amyloidotic polyneuropathy [9]. CLU binds
promiscuously to a wide range of misfolded client proteins
and either sequesters them into stable, soluble complexes
(in the case of proteins forming amorphous aggregates) or
inhibits the formation and accumulation of toxic amyloid
assemblies [10, 11]. Clusterin is a particularly potent
chaperone and can inhibit protein aggregation at molar ra-
tios of chaperone:client protein that are significantly lower
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than those needed by other chaperones [12, 13]. Extracellu-
lar CLU-client protein complexes are susceptible to endo-
cytic clearance by monocytes and hepatocytes, and this
action is thought to form a central plank in the operation
of a co-ordinated system to maintain extracellular protein
homeostasis (proteostasis) [14].
Whilst CLU is predominantly a secreted protein, mul-
tiple independent studies have now clearly established
that during conditions of ER stress, CLU secretion is
inhibited, and full-length CLU exits the secretory system
to enter the cytosol. Firstly, the translocation of mature
CLU from the ER/Golgi into the cytosol of human astro-
cytoma U251 cells in response to ER stress was shown
by two complementary biochemical and immunofluores-
cence approaches [15]. Subsequently it was demon-
strated that the ER-resident chaperone BiP (GRP78)
facilitates the translocation of CLU to the cytosol during
ER stress in human prostate cancer LNCaP cells [16]. In
addition, it was recently shown that during ER stress in
PC3 and LNCaP cells, cytoplasmic CLU interacts with
LC3 to promote autophagy [17]. While the mechanism
by which CLU translocates from the ER lumen to the
cytosol in response to stress is yet to be elucidated, it ap-
pears that the release may form a part of a larger strat-
egy in which many different chaperones are released
from the ER to the cytosol to defend the cell against
intracellular stresses. This has been suggested by the
demonstration that, in response to cytosolic foreign
DNA or inhibition of the proteasome, BiP is released to
the cytosol [18]. Other earlier studies have also sug-
gested that CLU might be involved in stress responses
within the cell. For example, CLU accumulates in cells
when either lysosomal degradation or the proteasome
are specifically inhibited [19], and CLU is itself ubiquiti-
nated during ER stress (a process that can only occur in
the cytosol) [15]. Furthermore, other studies have sug-
gested that CLU promotes ubiquitination and proteoso-
mal degradation of the cytosolic proteins, COMMD1
and IkB [20] and the lysosome-mediated degradation of
the cell-surface copper transport proteins, ATP7A and
ATP7B [21, 22]. Collectively, the previous literature
points to a potential involvement of CLU, especially dur-
ing ER stress, in facilitating the degradation of specific
cell proteins via both of the primary cell degradative
pathways, the proteasome and autophagy.
The pathologies of many neurodegenerative diseases
are known to involve both ER stress and cytotoxic pro-
tein aggregation [23]. Consequently, we examined
whether increased expression of the unusually potent
chaperone CLU could provide protection against intra-
neuronal protein aggregation and proteotoxicity, espe-
cially under conditions of ER stress. As a primary model,
we studied the aggregation of the 43 kDa transactive re-
sponse DNA-binding protein (TDP-43), which is implicated
in the pathology of amyotrophic lateral sclerosis (ALS),
where it translocates from its normal location in the nu-
cleus and forms insoluble inclusions in the cytoplasm. We
investigated the ability of CLU to influence the aggregation
and clearance of TDP-43 in vitro, in neuronal cells and in
transgenic Drosophila melanogaster. The results indicate
that CLU can interact with TDP-43 and potently inhibit its
aggregation, and that in a neuronal cell model undergoing
ER stress, CLU reduces the numbers of cytoplasmic TDP-
43 inclusions. We further show in transgenic Drosophila
that co-expression of CLU reduces cytoplasmic mislocaliza-
tion of TDP-43 in motor neurons, protects against loss of
locomotor activity and significantly extends lifespan. Lastly,
we showed that in Drosophila photoreceptor cells, CLU
gave ER stress-dependent protection against proteotoxicity
arising from both Huntingtin-Q128 and mutant (R406W)
human tau.
Materials and methods
Cell culture and in vitro methods
Transfection, immunocytochemistry and confocal imaging
of mammalian cells
SH-SY5Y, N2a and U251 cells were grown in DMEM/
F12 (Life Technologies) supplemented with 10% (v/v)
foetal calf serum (Bovogen) either on glass coverslips in
12 well microplates or 8 well glass bottom μ-Slides
(Ibidi). When cells were 60-80% confluent they were
transfected as indicated with either pCAG-EGFP/RFP
(encoding the wild-type TDP-43-tdTomato fusion pro-
tein (Addgene plasmid 28,205) using X-tremeGENE HP
(Roche), pRc/CMV-HT7 (encoding human CLU; [24]),
pEGFP-N1-TDP-CTF (encoding a ~ 20 kDa C-terminal
fragment (residues 216-414) of human TDP-43 fused to
enhanced green fluorescent protein (EGFP); Addgene
plasmid #28197) or pCMV6-AC-(M337 V)TDP-43-tGFP
(Origene; M337 V mutation introduced into the wild
type human TDP-43 sequence, fused at the C-terminus
to turboGFP) using Lipofectamine 2000 (Life Technolo-
gies) according to the manufacturer’s instructions. 48 h
after transfection, cells were treated (or left untreated)
for 10 h with 2.5 μM A23187, 2.75 μM Tg and/or 10 μM
MG132 (all from Sigma). The cells were immunostained
for CLU as follows. Cells were first chemically fixed by
incubation for 15 min on ice in 4% (w/v) paraformalde-
hyde in phosphate buffered saline (PBS; 135 mM NaCl,
10 mM Na2PO4, 2.7 mM KCl, 1.75 mM KH2PO4,
pH 7.4), then permeabilized by a 20 min incubation on
ice in 0.5% (v/v) TX-100 in PBS. Mouse hybridoma
culture supernatants containing IgG1 G7 (anti-human
CLU) or DNP9 (anti-2,4-dinitrophenyl) monoclonal
antibodies [11] (both diluted 1:2 in 1% w/v bovine serum
albumin (BSA) in PBS) were used as primary antibodies.
These were detected using goat anti-mouse Ig conju-
gated with Alexa Fluor-488 or Alexa Fluor-555 IgG
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(ab150113 and ab150114, Abcam) (2 μg/ml). The nuclei
were then stained with RedDot2 (Biotium) according to
the manufacturer’s instructions. The cells were washed
with PBS after each staining step. Cells grown on cover-
slips were mounted on a glass slide using Citifluor™
CFPVOH and AF100 anti-fadent (ProSciTech). Imaging
was performed on a Leica TCS SP5 II confocal micro-
scope using Leica Application Suite Advanced Fluorescence
version 2.6.1-7314. Sequential excitation was performed
using 488 nm, 561 nm and 633 nm lasers and fluorescence
emissions collected at 500-540 nm (for the 488 nm laser),
570-620 nm (for the 561 nm laser) and 650-750 nm (for
the 633 nm laser). In co-localization analyses, to determine
the Manders’ overlap coefficient, images were first back-
ground subtracted using ImageJ. Regions of interest were
then drawn around the cells to exclude pixels lacking inten-
sity in both fluorescence channels (zero - zero pixels) and
the extent of co-localization was quantified using the Coloc
2 function in ImageJ with Costes thresholding.
Immunoprecipitation of CLU from N2a cell lysates
N2a cells were transfected to express TDP-43M337V-tGFP
(Origene) and human CLU using Lipofectamine 2000
transfection reagent according to the manufacturer’s in-
structions (Life Technologies). Some cells were trans-
fected to express only TDP-43M337V-tGFP or CLU. Cells
(200,000 in all cases) were harvested with trypsin/EDTA
and washed twice with PBS (300 x g, 5 min) before being
lysed on ice for 5 min in 150 μl PBS containing 1% (v/v)
TX-100 and Complete Protease Inhibitor Cocktail
(Roche). Any insoluble material was pelleted (21,000 x g,
15 min, 4 °C) and the cleared lysate (130 μl) was gently
mixed overnight at 4 °C with Sepharose beads (~ 20 μl
packed volume) coupled with mouse monoclonal G7
anti-CLU antibody. In some cases purified human CLU
or BSA (100 nM) was added directly to the lysate imme-
diately prior to the addition of the Sepharose beads. The
beads were then washed 4 times in PBS (10 min, 2000 x
g, 4 °C) before the bound proteins were eluted from the
beads by boiling for 5 min in 25 μl SDS sample buffer.
The beads were removed by centrifugation (2000 x g,
10 min) and the eluted proteins (~ 20 μl) analysed by
Western blotting for the presence of TDP-43 as de-
scribed below.
Western blotting
Proteins electrophoresed through a 10% SDS-polyacrylamide
gel were transferred onto a nitrocellulose membrane (Sartor-
ius) at 4 °C overnight (20 V) using a Western Transfer Unit
(BioRad). The membrane was then blocked for 1 h at room
temperature (RT) with blocking buffer (5% (w/v) skim milk
in PBS containing 0.1% (v/v) TX-100). The membrane was
then incubated with TARDBP monoclonal antibody (clone
2E2-D3, Abnova; 1:500) followed by an HRP-conjugated
goat-anti-mouse IgG antibody (DAKO; 1:2000). Each anti-
body was diluted into blocking buffer, and each incubation
was followed by washing the membrane 3X with PBS con-
taining 0.1% (v/v) TX-100, followed by 3X washes with PBS.
Bound antibodies were detected using Supersignal West Pico
Chemiluminescence Substrate (Thermo Fisher Scientific),
according to the manufacturer’s instructions. Bands were
detected using X-ray film (Amersham Hyperfilm; GE Life
Sciences).
Measurement of TDP-43 inclusions in N2a cells
This was done essentially using the method described in
[25], which uses flow cytometric analysis to determine
the transfection efficiency, and in cell lysates enumerate
(i) fluorescent inclusions formed by the aggregation of
fluorescent fusion proteins, and (ii) concurrently, the
number of cell nuclei. This allows calculation of the
number of fluorescent protein inclusions per 100 trans-
fected cell nuclei. N2a cells grown in 24 well plates were
transfected to express TDP-43M337V-GFP and cultured
for 10 h with or without thapsigargin (2.75 μM), A23187
(2.5 μM), MG132 (10 μM), chloroquine (50 μM), bafilo-
mycin A1 (100 nM), U0126 (60 nM), rapamycin
(1.5 μM), or combinations of the preceding. Cells were
then harvested using 0.5% trypsin/EDTA, washed and
resuspended in 500 μl of PBS. To estimate transfection
efficiency, a 150 μl aliquot of the cell suspension was
analysed, together with an aliquot of untransfected N2a
cells, by flow cytometry using an LSRFortessa X-20 (BD
Bioscience). GFP fluorescence was measured using
488 nm excitation and 525/50 nm emission. The
remaining cells were lysed in 0.5% (v/v) Triton X-100 in
PBS, containing RedDot2 (1:1000; Biotium) to stain nu-
clei and Complete protease inhibitor (Roche). The lysate
was analyzed by flow cytometry measuring forward and
side scatter, and the fluorescence of GFP (acquired as
above) and RedDot2 (640 nm excitation, 670/30 nm
emission); data was analyzed as described above.
In vitro aggregation assay for TDP-43 peptide
CLU was purified from human plasma obtained from
Wollongong Hospital (Wollongong, NSW, Australia) as
previously described [11]. The synthetic peptide corre-
sponding to residues 286-331 of TDP-43 (TDP-43286-331)
was obtained from China Peptides and Thioflavin T
(ThioT) from Sigma. TDP-43286-331 was dissolved in
MilliQ water (adjusted with NaOH to pH 11.3) followed
by the addition of a one tenth volume of buffer (1 M
NaCl, 0.5 M HEPES, pH 7.4), to give a final concentra-
tion of approximately 448 μM TDP-43286-331. This solu-
tion was then diluted with an equal volume of 100 mM
NaCl, 50 mM HEPES, pH 7.4, containing other additions
(or not) to give a final concentration of 224 μM TDP-
43286-331 with or without 2 μM SOD1 or 0.22, 0.022,
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0.011, or 0.008 μM CLU. These solutions were incubated
at 37 °C whilst shaking for 16 h in a 384 well microplate.
ThioT (20 μM) was added to each well prior to incuba-
tion in a FLUOstar OPTIMA (BMG LABTECH) with an
excitation filter of 440 +/− 10 nm and an emission filter
of 490 +/− 10 nm. SOD1 was also incubated without the
addition of TDP-43 and no significant change in fluores-
cence emission was detected over the time course (data
not shown).
In vitro translation and aggregation assay for TDP-43-tGFP
cDNA encoding a human TDP-43-tGFP construct was
cloned into pT7CFE1-CHis (Thermo Fisher Scientific).
Both the cloning and the verification of insertion by
sequencing were performed by GenScript. Full length
human TDP-43-tGFP was expressed using the TnT® T7
Quick Coupled Transcription/Translation System (Promega)
in a POLARstar Omega plate reader (BMG LABTECH)
according to the manufacturer’s instructions (30 °C for
90 min). After the reaction was complete a final yield of
43 nM was estimated (based on manufacturer’s specifica-
tions) and the mixture was centrifuged to remove any aggre-
gated material (16,600 x g, 10 min, 4 °C). The supernatant
was incubated at either 4 °C or 37 °C for 5 h to induce
aggregation with or without the addition of CLU or
BSA (both at 43 nM). Following this incubation the
samples were centrifuged again as above to pellet any
aggregated protein. The supernatant containing any
soluble TDP-43-tGFP was collected and 5 μl was di-
luted 1:1 with 2X SDS sample buffer supplemented
with 1% β-mercaptoethanol and boiled for 5 min. The
proteins were separated by SDS-PAGE and analysed by
Western blot, probing for TDP-43, as described above.
Transgenic Drosophila methods
Generation of transgenic Drosophila
Drosophila expressing HA-tagged human TDP-43 were
created previously [26]. Following the same procedure,
the human CLU construct was codon optimised for ex-
pression in Drosophila and synthesised by Genscript,
then cloned into the multiple cloning site of pUAST-
AttB. Differences in expression of the constructs that
could arise from their integration at different genomic
loci were eliminated as the vectors contain sites for
exploiting the PhiC31 system for site-specific integration
of transgenes [27]. CLU expression was under the
control of the UAS-GAL4 system [28]. All injected
constructs, including an empty pUAST plasmid for the
control line, were incorporated at the same genomic
locus (51D) on Chromosome II (Bestgene Inc.). All
Drosophila lines were made isogenic by repeated back-
crossing. Htt-Q128 and Htt-Q72-GFP flies were a gift of
Hyung Don Ryoo (NYU). All other Drosophila stocks
used were obtained from Bloomington Stock Centre.
Hemolymph extraction
Drosophila were decapitated and the bodies were placed
with the thorax pointing downwards into a p200 pipette
tip. Four decapitated Drosophila were placed sequentially
into each tip and three tips were placed in to a 1.5 ml
Eppendorf tube on ice. The Eppendorf tube was centri-
fuged for 15 min at 4000 x g in an Eppendorf desk-top
microfuge at 4 °C. Approximately 1 μl of straw-coloured
hemolymph was collected from each Eppendorf tube and
was flash frozen in liquid nitrogen and stored at −80 °C.
The total protein concentration of each hemolymph sam-
ple was determined by bicinchoninic acid microprotein
assay and Western blot detection was carried out using
20 μg of hemolymph protein loaded per lane.
Deglycosylation of head lysate proteins
1-20 μg of protein (hemolymph or Drosophila head
homogenate) was diluted in 20 μl H2O. To this solution
2 μl Nonidet P40 (NP40), 2 μl G7 buffer and 1 μl PNGa-
seF (all reagents from NEB deglycosylation kit) were
added according to the manufacturer’s instructions.
After gentle agitation for 6 h at RT, the samples were
analysed by Western blotting under non-reducing condi-
tions. These conditions are sufficient to remove virtually
all sugars [29].
Western blot analysis of fly head homogenates
Five Drosophila per genotype were decapitated, homoge-
nised in RIPA buffer: [50 mM Tris HCl at pH 8,
150 mM NaCl, 1% (v/v) TX-100, 0.5% (w/v) sodium
deoxycholate, 0.1% (w/v) SDS and protease inhibitors
(Roche), then centrifuged in an Eppendorf desk-top
microfuge at 20000 x g for 30 min in order to pellet
insoluble proteins. The pellets were dissolved in de-
naturing buffer (9 M urea, 1% SDS, 25 mM Tris, 1 mM
EDTA) at 4 °C, sonicated at 42000 Hz for 30 s, and cen-
trifuged as above for a further 30 min at 20000 x g to
pellet any still insoluble proteins. The supernatant (urea-
soluble proteins) was used as the insoluble fraction.
Protein samples were separated on 4-12% Bis-Tris gels
(Invitrogen) and transferred to PVDF membrane
(Millipore). Blots were blocked with 5% (w/v) non-fat
milk in 0.05% (v/v) TX-100/PBS, and then incubated
with the following primary antibodies: rat anti-HA-
biotin, High Affinity (3F10) antibody which reacts with
the N-terminal HA-tag on the TDP-43 construct (Roche;
1:1000); rabbit polyclonal anti-TDP-43 antibody (Pro-
teintech; 1:2500); mouse anti-CLU G7 and 41D [11]
hybridoma culture supernatant (1:10); rabbit anti-
phospho-eIF2alpha (Ser51) (Cell Signalling; 1:1000).
Blots were washed 6 times for 10 min with gentle agitation
at RT in 0.1% (v/v) TX-100/PBS and then incubated with
anti-rat, anti-rabbit or anti-mouse secondary antibodies
conjugated to HRP (DAKO; 1:5000). All antibodies were
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diluted in the blocking buffer specified above. Bands were
detected using a SuperSignal® West Pico Substrate kit
(Thermo Fisher Scientific).
Detection of UPR
A reporter construct, gift of Hyung Don Ryoo (NYU),
was created so as to have an enhanced green fluorescent
protein (EGFP) inserted after the IRE-1 splice site in
XBP1, so that EGFP would only be in frame after XBP1
had been spliced by IRE-1; the splicing of XBP1 by IRE-
1 only occurs when there is activation of the UPR,
leading to EGFP expression [30]. We co-expressed this
construct with each of TDP-43, Htt-Q128 and mutant
(R406W) human tau, using a gmr-GAL4 promoter and
homogenized the heads of 10 adult Drosophila per ex-
periment, 24 h following eclosion. These samples were
then prepared for Western blot as above. The presence
or absence of EGFP (and thus UPR activation) was
detected by an EGFP specific antibody (mouse monoclo-
nal anti-EGFP antibody, Abcam; 1:2000) and an anti-
mouse Ig-HRP secondary antibody as above. In similar
experiments, the Western blots were instead probed
with rabbit anti-phospho-eIF2alpha (Ser51) antibody
(Cell Signaling Technology; 1:1000) to detect phosphory-
lated eIF2α, an independent marker of the UPR [31].
Drosophila immunohistochemistry
Third-instar larval imaginal eye discs and adult eyes
were dissected in PBS, fixed in 4% (w/v) paraformalde-
hyde (PFA) in 0.05% (v/v) TX-100 in PBS for 20 min at
RT then permeabilised for 20 min at RT in 0.5% (v/v)
TX-100/PBS, before blocking for 30 min in 5% (w/v)
BSA in 0.05% TX-100/PBS. Subsequently, fixed and per-
meabilised discs were incubated overnight with rat anti-
HA-biotin high affinity antibody (Clone 3F10, Roche)
and mouse anti-CLU antibody (G7), as above. Samples
were then incubated overnight in streptavidin Alexa
Fluor 594 conjugate (Invitrogen; 1:10,000) and anti-
mouse Alexa Fluor 488 conjugate (Invitrogen; 1:1000).
All antibodies were diluted in the blocking buffer de-
scribed above. Tissue was counterstained with TOTO-3
(Invitrogen; 1:10,000) diluted in 0.05% TX-100/PBS to
detect nucleic acids.
Light and scanning electron microscopy of Drosophila eyes
Light and fluorescence microscopy: Drosophila expressing
TDP-43 +/− CLU or Htt-Q72-GFP +/− CLU were
crossed with gmr-GAL4 Drosophila (Bloomington Stock
ID: 1104 & 8121) and maintained in a temperature and
humidity controlled incubator at 25°C and 70% humid-
ity. Images were taken of 1-day-old transgenic offspring
using 7.5X objective and a Leica epifluorescence micro-
scope; imaginal eye disks prepared as above were imaged
using a Leica SP confocal microscope. Scanning electron
microscopy: Samples were prepared by fixing whole adult
Drosophila overnight in 2.5% glutaraldehyde in 0.1 M
PBS (pH 7.4) at 4°C, then dehydrated with an ethanol
series. Finally, samples were mounted on stumps and
sputter coated using 20 nM Au/Pd in a Polaron E5000.
SEM images were collected using a Philips XL30 micro-
scope at 200× magnification.
Climbing assays
Motor function was assessed by a negative geotaxis
assay. Drosophila were generated that expressed TDP-43
(with and without CLU), or CLU alone, in motor
neurons from the day of hatching. Non-transgenic Dros-
ophila were also tested as a control group. For each
treatment group, three vials each containing ten Dros-
ophila were analysed every second day. A climbing index
score was calculated as described previously [32]. The
average climbing index for the three replicate analyses
was calculated for each time point and plotted against
time since eclosion (n = 30).
Survival assays
Drosophila were generated at 18°C where Gal80 inhibits
GAL4 dependent transcription, thus preventing expres-
sion of transgenes in embryos and larvae. Adult Dros-
ophila were moved from 18°C to 29°C (Gal80 is inactive
at this temperature and so no longer inhibits expression
of transgenes) within 24 h of eclosion; they were then
transferred to fresh food and counted every 2-3 days.
Gal80; D42-GAL4 is activated by heat shock at 29°C and
induces expression in motor neurons. Each treatment
group was comprised of 90 non-virgin female Drosophila
maintained in glass vials (10 per vial). Median survivals
were calculated using Kaplan Meier survival statistics
and differences between genotypes were analysed using
a Mann-Whitney U test.
Results
ER stress induces CLU to co-localize with cytoplasmic
TDP-43-GFP inclusions
Previous studies have shown that ER stress induces re-
lease of CLU to the cytosol [15–17]. We confirmed that,
as expected, CLU was detected in the cytosol fraction
prepared from N2a cells chemically treated to induce ER
stress but not in the same fraction prepared from un-
treated cells (Additional file 1: Figure S1). Furthermore,
analysis of the anterior horn cells (motor neurons) in
human post-mortem spinal cord sections of three ALS
patients and three age-and sex-matched control cases,
revealed a striking difference in CLU staining, consistent
with the release of CLU from the ER in ALS affected
neurons (Additional file 1: Figure S2). In control cases
CLU staining mirrored Nissl substance staining, consist-
ent with its localization in the ER (secretory pathway).
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However, in the anterior horn cells of ALS cases, which
exhibited prominent pathological cytoplasmic TDP-43
inclusions, CLU staining was increased and exhibited a
more diffuse staining pattern. The pattern of CLU stain-
ing in these cells no longer mirrored the distribution of
Nissl substance, consistent with a change in the subcel-
lular localization of CLU (Additional file 1: Figure S2).
We next examined the effects of CLU over-expression
in a cell model of protein mislocalization relevant to
ALS. TDP-43 is a member of the hnRNP family of RNA
binding proteins whose functions involve the regulation
of RNA splicing and transcription. In almost all cases of
sporadic and also in some familial cases of ALS, this pre-
dominantly nuclear protein becomes mislocalized in
motor neurons to the cytoplasm, where it forms ubiqui-
tinated and hyper-phosphorylated inclusions enriched in
proteolytically generated C-terminal fragments of TDP-
43 [33]. When N2a (or SH-SY5Y neuroblastoma) cells
were transiently transfected to express an aggregation-
prone C-terminal fragment of TDP-43 fused to GFP
(TDP-43CTF-GFP), which forms aggregates with struc-
tural similarity to those in human post-mortem tissue
and that is widely used as a tool to study TDP-43 aggre-
gation [33], they developed cytoplasmic inclusions read-
ily detected by confocal microscopy. Furthermore,
consistent with ER stress inducing release of CLU to the
cytosol, CLU was found co-localized with TDP-43CTF-
GFP inclusions in ER stressed N2a cells, but not in un-
stressed N2a cells (Fig. 1a; Additional file 1: Figure S3).
ER stress also induced co-localization of CLU with inclu-
sions formed by a similar fusion protein (mutant M337
TDP-43 fused at the C-terminus with GFP; TDP-43M337V-
GFP) in U251 human glioblastoma cells (Additional file 1:
Figure S3). We also used co-immunoprecipitation analysis
to show that soluble TDP-43M337V-GFP is physically
associated with CLU in lysates prepared from co-
transfected N2a cells, for both untreated cells (Fig.
1b) and cells treated to induce ER stress (not shown).
Interestingly, we also used a monoclonal antibody
specific for human CLU to show that exogenous hu-
man CLU added (“spiked”) to lysates of transfected
N2a cells co-immunoprecipitated with TDP-43M337V-
GFP. These results demonstrate that when CLU and
TDP-43M337V-GFP are both present in cell lysates
they can form complexes, regardless of whether or
not the two proteins may have been in different cell
compartments prior to lysis. Thus, while it is not
possible to use a co-immunoprecipitation approach to
verify the occurrence of CLU-TDP-43 complexes in
situ inside cells, the results indicate that if the two
proteins are present within the same compartment,
such as suggested by the confocal images of cytoplas-
mic co-localization, they are capable of forming
complexes.
CLU potently inhibits TDP-43 aggregation in vitro
Full length TDP-43 is so aggregation-prone that it is ex-
tremely difficult to express the full length protein in bac-
teria as a soluble recombinant product in significant
quantities [34]. We therefore initially made use of a
well-characterised 46-mer peptide corresponding to a re-
gion of the C-terminal domain of TDP-43 (TDP-43286-
331), which is known to form fibrillar aggregates [35], to
probe the ability of CLU to inhibit the in vitro aggrega-
tion of TDP-43. Under the conditions tested, following a
2 h lag phase, the TDP-43286-331 peptide rapidly formed
ThioT positive aggregates. Under these same conditions,
a CLU:peptide ratio of 1:1000 completely inhibited the
appearance of ThioT positive species over a 16 h time
course. Even at a 1:25,000 ratio, CLU retarded TDP-
43286-331 fibril formation by about 2 h (Fig. 2a). This ef-
fect is specific to CLU, as even when used at a ratio of
1:500, a non-chaperone control protein (bovine super-
oxide dismutase 1, SOD1) had negligible effects on
aggregation of the peptide (Fig. 2a). In order to confirm
that CLU can also suppress the aggregation of full-length
TDP-43, we adapted an in vitro protein expression system
for full-length TDP-43-turboGFP (TDP-43-tGFP) de-
scribed in [34]. Following in vitro expression, a significant
amount of full-length TDP-43-tGFP remained soluble for
4 h at 4°C, but after a 4 h incubation at 37°C in the pres-
ence of 43 nM BSA (a non-chaperone control protein),
very little TDP-43-tGFP remained soluble (Fig. 2b). When
incubated for 4 h at 37 °C, the presence of 43 nM CLU re-
sulted in an 8-fold higher level of TDP-43-tGFP remaining
in solution (Fig. 2b), demonstrating that CLU is able to
very significantly inhibit the aggregation of full-length
TDP-43 in vitro.
CLU expression specifically reduces the numbers of
cytoplasmic TDP-43-GFP inclusions in ER stressed N2a
cells
We used a recently developed flow cytometry method,
which counts fluorescent particles in cell lysates and
normalizes this count against the number of separately
enumerated nuclei (FloIT; [25, 36, 37]) to quantify the
numbers of TDP-43M337V-GFP inclusions in differently
treated N2a cells. The results indicated that (i) in un-
stressed cells, overexpression of CLU or mCherry had
no significant effect on the numbers of TDP-43M337V-
GFP inclusions, (ii) the numbers of inclusions were in-
creased in cells treated with either thapsigargin (Tg)
alone (to induce ER stress), or with Tg and MG132 (the
latter to also inhibit the proteasome), and (iii) overex-
pression of CLU, but not mCherry, reduced the numbers
of TDP-43M337V-GFP inclusions in ER-stressed cells (Fig.
2c). CLU overexpression also specifically reduced the
number of TDP-43M337V-GFP inclusions in N2a cells in
which ER stress was induced by the addition of Ca2+
Gregory et al. Acta Neuropathologica Communications  (2017) 5:81 Page 6 of 16
ionophore A23187 (Additional file 1: Figure S5A). The
overexpression of CLU or mCherry had no significant
effect on the numbers of inclusions in unstressed cells
(Additional file 1: Figure S5B).
Human CLU is glycosylated, cleaved and secreted when
expressed in Drosophila neurons
Given the ability of CLU to reduce the number of TDP-43
inclusions in cultured neuronal cells, we next developed a
whole organism model in which the protective effects of
CLU against cellular proteotoxicity could be further inves-
tigated. Drosophila has no identifiable homologue of clus-
terin. When expressed in photoreceptor neurons, human
CLU was detected in juxtanuclear puncta distributed uni-
formly across the eye disc (Fig. 3a). This distribution is
consistent with the protein being localised in the secretory
pathway and analysis of the hemolymph (the circulatory
fluid of Drosophila) confirmed that CLU is secreted from
the neurons in which it is being expressed (Fig. 3b). Non-
reducing SDS-PAGE and Western blot analysis of head
lysates from Drosophila expressing CLU revealed that the
protein was abundantly expressed and migrated as a single
band with an apparent molecular mass of ~ 55 kD; it mi-
grated at a lower molecular mass (~ 50 kD) when the
sample was treated with PNGase to remove virtually
all glycosylation (Additional file 1: Figure S6A). The
Fig. 1 CLU co-localizes with cytoplasmic TDP-43 inclusions in ER stressed cells and co-precipitates with TDP-43-GFP. a N2a cells transfected to
express TDP-43CTF-GFP and human CLU (hCLU) were treated as indicated, fixed/permeabilized, then immunostained for hCLU. White arrowheads
indicate the positions of inclusions. Overlay panels (right): where there is no colocalization, inclusions appear green; colocalization of TDPCTF-GFP
and CLU appears as white. Scale bar is 10 μm; images shown are representative of many. Manders overlap coefficients (TDP-43CTF-GFP and CLU),
calculated using at least 20 cells for each treatment, were: untreated, 0.13 +/− 0.14; Tg, 0.62 +/− 0.07; A23187, 0.52 +/− 0.09 (mean +/− SD). See
also Additional file 1: Figure S3. b TDP-43 immunoblot showing that TDP-43M337V-GFP co-precipitated with hCLU from lysates of co-transfected
N2a cells and also when exogenous purified hCLU (but not BSA) was added (“spiked”) to lysate prepared from N2a cells transfected to express
only TDP-43M337V. The black arrow indicates the expected size of TDP-43M337V-GFP. Key above image indicates which protein(s) cells were
transfected to express (Trans), and the protein added to the lysate (Spike). The result shown is representative of two independent experiments
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molecular mass of CLU detected in the hemolymph
and head lysates of Drosophila is, however, less than
that of CLU purified from human plasma (~ 55 kD
versus 75-80 kD), a difference attributable to the fact
that insect cells glycosylate proteins to a lesser extent
than mammalian cells [38]. Indeed, enzymatic degly-
cosylation of CLU expressed in Drosophila results in
a smaller loss in apparent mass than for CLU from
human plasma, and the deglycosylated forms of both
proteins migrate at a very similar position when ana-
lyzed by SDS-PAGE (Additional file 1: Figure S6A).
Differences in glycosylation do not, however, signifi-
cantly affect the function of CLU, as indeed the
removal of virtually all the attached carbohydrates
does not inhibit its chaperone activity [29]. We also
confirmed by SDS-PAGE that Drosophila-expressed
CLU dissociates into α- and β-subunits when chem-
ically reduced, as seen for CLU from human plasma
(Additional file 1: Figure S6B). A faint CLU band de-
tected at about 50 kDa may represent a minor glyco-
form of CLU, as glyco-variants of CLU are found in
human plasma [39]. Taken together, these biochemical
studies indicate that Drosophila neurons are able to
synthesise and secrete a mature, post-translationally
modified form of human CLU.
TDP-43 expression induces ER stress and cellular
retention of CLU in transgenic Drosophila
We first co-expressed both TDP-43 and a fluorescent re-
porter of the unfolded protein response (an EGFP-based
reporter of the alternative splicing of XBP1 [30]) in
photoreceptor neurons of the Drosophila eye. For com-
parison, we also examined the effects of expression both
of exon 1 of the Htt gene, containing a 128 glutamine
residue expansion (Htt-Q128; [40]), and also of mutant
(R406W) human tau, which is associated with fronto-
temporal dementia with parkinsonism-17 (FTDP-17)
[41]. Co-expression of the fluorescent UPR reporter with
TDP-43, Htt-Q128 or R406W tau followed by analysis of
EGFP levels by Western blotting, revealed that IRE1-
dependent splicing of XBP1-EGFP was induced by ex-
pression of TDP-43 but not by the expression of either
Fig. 2 CLU inhibits TDP-43 aggregation and reduces the number of TDP-43-GFP inclusions in neuronal cells during ER stress. a TDP-43286-331
(peptide) was incubated at 37 °C with shaking, in the presence of either CLU or the non-chaperone control protein bovine superoxide dismutase
(SOD1), at the molar ratios indicated in the key. Peptide aggregation was monitored by ThioT fluorescence. Data are means +/−SE (n = 4).
b Upper panel: Image of Western blot detecting soluble TDP-43-tGFP after incubation at 4 °C, or 37 °C (which increases aggregation), with or
without CLU or BSA (a non-chaperone control protein). Black arrow indicates position of monomeric TDP-43-tGFP, upper bands represent soluble
oligomers. Loading control (colored dye from Promega transcription/translation kit) shown at bottom. Lower panel: Densitometric quantification
of blot results (means + SD, n = 3). c Transfected N2a cells were treated as indicated for 10 h (key below plot), then lysed and TDP-43M337V-tGFP
inclusions enumerated by flow cytometry; data plotted as % change relative to untreated cells (means + SEM, n = 4; untreated cells are defined
as the 100% value). See also Additional file 1: Figure S5. For all panels, results shown are representative of two or more independent experiments.
In (b) and (c), horizontal bars indicate pairwise comparisons, * p < 0.05, ** p < 0.01, *** p < 0.001 (1-way ANOVA with Newman-Keuls post-test (b),
or 2-way ANOVA with a Bonferroni post-test (c))
Gregory et al. Acta Neuropathologica Communications  (2017) 5:81 Page 8 of 16
Htt-Q128 or R406W tau (Fig. 3c). The induction of ER
stress by TDP-43 expression was also confirmed by
Western blot analysis showing that the levels of phos-
phorylated eIF2α, an independent marker of the UPR
[31], were much higher in homogenates of the heads of
Drosophila expressing TDP-43 compared to those of
control Drosophila (Additional file 1: Figure S6C).
Western blotting was also used to confirm that CLU was
secreted into the hemolymph when expressed alone in
photoreceptor neurons, but that it was barely detectable
in this fluid when co-expressed with TDP-43 in the same
cells (Fig. 3d). We next expressed CLU in Drosophila
motor neurons and examined its distribution in brains
by confocal microscopy. Despite the limited resolution
of confocal images obtained from the relatively thick
adult Drosophila brain, it can be seen that, consistent with
its secretion, CLU was diffusely distributed throughout
the neuropil (Fig. 3e i & ii), and was not co-localized with
neuronal cell bodies or axons. When co-expressed with
TDP-43, however, CLU was found at high levels in the
axons (Fig. 3e iii & iv).
CLU restores nuclear localization of TDP-43 in adult
Drosophila motor neurons
In the motor neurons of 10 day old adult Drosophila
brains, when expressed alone, TDP-43 is frequently
Fig. 3 Expression of CLU and TDP-43 in Drosophila. a Confocal microscopy images of imaginal eye discs of third instar larvae expressing human
CLU in the photoreceptor cells; CLU (green), TOTO-3 (blue, detects nuclei). Left panel: Large white arrow indicates the morphogenetic furrow (scale
bar 100 μm); white box represents the area shown at higher magnification in the large panel to the right. Right panel: Punctate staining of CLU
(scale bar 10 μm); the inset white box shows a region with still higher magnification (arrowheads indicate CLU). b Non-reducing Western blots of
Drosophila head homogenates, hemolymph (HL), and the positive control (human plasma CLU); expression of CLU indicated above the lanes.
c Western blot of whole Drosophila head lysates, prepared from non-transgenic (Non-TG) Drosophila, or Drosophila expressing TDP-43, Htt-Q128
or Tau R406W; detection of XBP1-EGFP indicates activation of the UPR (β-actin was used as a loading control). d Western blot detecting CLU in
hemolymph taken from Non-TG Drosophila, and those expressing CLU +/− TDP-43; equal amounts of hemolymph were loaded in each lane
under non-reducing conditions. See also Additional file 1: Figure S6. e Confocal microscopy images of the central lobe of 10-day-old, whole adult
Drosophila brains expressing CLU +/− TDP-43 in the motor neurons. Images in (i) and (iii) encompass the entire central lobe; the central region in
each image contains neuronal process and axons. Images in (ii) and (iv) represent optical zooms of the areas indicated by the white boxes in (i)
and (iii), respectively. Scale bars in (i) and (iii) represent 50 μm, while those in (ii) and (iv) represent 5 μm. CLU (green), white arrowheads in (iv)
indicate axons. Results shown are representative of two or more independent experiments
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notably absent from its normal nuclear localization
(elipses devoid of TDP-43; Fig. 4a i & ii) and is instead
detected in foci localized within the cytoplasm of the
motor neurons (white arrowheads; Fig. 4a i) as well as
being diffusely distributed throughout the soma, axons
and neuronal processes (white arrowheads; Fig. 4b i &
ii). This observation is consistent with those made in
yeast models in which high levels of expression of wild-
type TDP-43, as achieved in the current Drosophila
model, result in its mislocalization into the cytosol [42].
When CLU is co-expressed with TDP-43, however, the
latter is no longer evident within the axons or neuronal
processes and paranuclear foci of TDP-43 are no longer
visible. Instead, TDP-43 is predominantly found within
the nucleus (Fig. 4a iii & iv) where it strikingly co-
localizes with CLU (Fig. 4c). At earlier stages of develop-
ment, when the two proteins have been co-expressed for
shorter periods of time, TDP-43 is largely absent from
Fig. 4 CLU expression reduces TDP-43 mislocalization in Drosophila neurons. Confocal microscopy images of: a Motor neuron cell bodies of 10-
day-old adult Drosophila brains expressing TDP-43 alone (i & ii) or together with CLU (iii and iv). Images (i & ii) and (iii & iv) represent the same
fields of view; TDP-43 (red; i & iii), TOTO-3 stained nuclei (grey; ii & iv). In (i), white arrowheads indicate paranuclear foci; in all panels white elipses
indicate nuclei (scale bars 5 μm). b Central lobe of adult Drosophila brains expressing TDP-43 +/− CLU. Images in (i) and (iii) were collected using
a 40X objective and encompass the entire central lobe (scale bars 50 μm); elipses show motor neuron cell bodies and the central region of each
image contains neuronal process and axons. Images in (ii) and (iv) represent optical zooms of the areas indicated by the white boxes in (i) and
(iii), respectively (scale bars 5 μm). TDP-43 (red), white arrowheads in (ii) indicate axons. c Motor neuron cell bodies of adult Drosophila brains co-
expressing CLU (green) and TDP-43 (red); TOTO-3 (white; nucleoli stain intensely, the rest of the nucleus stains less brightly); (iv) overlay of all three
images, yellow indicates co-localisation of CLU and TDP-43 (scale bars 7 μm). d Motor neuron cell bodies of third instar larval Drosophila brains
co-expressing CLU (green) and TDP-43 (red), TOTO-3 (blue); (iv) overlay of all three images; yellow indicates co-localisation of CLU and TDP-43
(scale bars 5 μm). e Reducing Western blot of the soluble and insoluble fractions of 10-day-old adult Drosophila head homogenate comparing
non-transgenic (non-TG) Drosophila and Drosophila expressing TDP-43 +/− CLU. β-actin was used as a loading control. Results shown are
representative of several independent experiments
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the nucleus and instead is found mainly in the cytoplasm
where it extensively co-localises with CLU (Fig. 4d).
Thus CLU co-expression results in the restoration in the
adult Drosophila of a predominantly nuclear localization
for TDP-43 and reduces the levels of both soluble and
insoluble TDP-43 detected in head lysates (Fig. 4e). This
effect cannot be attributed to lowered expression of TDP-
43 arising from transgene co-expression, as co-expression
of TDP-43 with GFP (which has no chaperone activ-
ity) has no effect on TDP-43 levels (Additional file 1:
Figure S7A).
CLU protects Drosophila motor neurons from TDP-43-
induced neurotoxicity
We next investigated whether CLU expression could
affect the neurodegenerative phenotypes resulting from
intracellular expression of TDP-43 in Drosophila motor
neurons. Strikingly, co-expression of CLU with TDP-43
in the motor neurons (i) significantly delays the onset of
locomotor dysfunction, increasing the time taken for
50% of TDP-43 expressing Drosophila to become immo-
bile from 5 days to 15 days (Fig. 5a), and (ii) increases
the median survival time by 33% compared to Drosoph-
ila expressing TDP-43 alone (from 15 ± 0.39 days to
20 ± 0.53 days; p = 0.0006, n = 180; Fig. 5b). This rescue
is specific to CLU expression, as co-expression of an un-
related protein (GFP; not expected to bind TDP-43)
driven by the same UAS-GAL4 system did not affect the me-
dian survival of TDP-43-expressing Drosophila (Additional
file 1: Figure S7B). Furthermore, CLU expression alone did
not cause a significant increase in the longevity of Drosoph-
ila. Non-transgenic Drosophila have a median survival of
36 days ±1.09 whereas CLU expressing Drosophila have a
median survival of 37 days ±1.18 (p = 0.5056 ns, n = 180;
Additional file 1: Figure S7C), indicating that the effects of
CLU are on neurotoxicity induced by TDP-43 rather than
representing a general effect on ageing.
CLU-mediated protection against intracellular
proteotoxicity is not restricted to TDP-43 and is
dependent on ER stress
We used the “rough eye” assay as a widely accepted tool
to assess neurotoxicity in Drosophila models, to test of
the effects of CLU expression on a variety of proteotoxic
stresses. The gmr-GAL4 promoter was used to express
TDP-43 in Drosophila photoreceptors, resulting in
neurotoxicity manifested as a depigmentation and struc-
tural derrangement of the ommatidia, which was signifi-
cantly reduced by CLU expression (Fig. 6a). We next
expressed two other neurotoxic proteins (Huntingtin-
Q128 (Htt-Q128) and mutant R406W human tau),
which we had earlier established did not induce ER
stress in Drosophila neurons (Fig. 3c). In both these
cases, CLU co-expression had no significant effect (Fig.
6a). We reasoned that the lack of protection against pro-
teotoxicity afforded by CLU in these models could relate
to its known dependence upon ER stress for release
from the ER to the cytosol. To examine this possibility
we next expressed in the Drosophila eye the Htt gene
(exon 1) with a 72 residue glutamine expansion, which
can be readily visualized through its fused EGFP tag
(Htt-Q72-EGFP) [43]. We then tested whether CLU co-
expression could protect from the resulting aggregation
and neurotoxicity during (i) basal conditions, and (ii)
chemically-induced ER stress induced by rearing Dros-
ophila on food supplemented with 5 mM DTT.
Western blot analysis of the XBP1-EGFP reporter in
Drosophila head homogenates showed that rearing Dros-
ophila on DTT-supplemented food is sufficient to induce
ER stress, indicated by induction of the UPR (Fig. 6b).
When comparing between Drosophila all co-expressing
Htt-Q72-EGFP and CLU, relative to Drosophila fed on
standard food, ER stressed Drosophila showed an ap-
proximately 70% reduction in the number of fluores-
cent Htt-Q72-EGFP puncta detected (440.4 ± 47.8 vs
138.4 ± 13.5; respectively; p = 0.0037, n = 9). This effect
Fig. 5 CLU expression reduces TDP-43 toxicity in Drosophila motor
neurons. Time-dependent differences between Drosophila expressing
TDP-43 +/− CLU in (a) motor function, measured by climbing assay,
and (b) survival, compared to non-transgenic (Non-TG) Drosophila. In
(a) and (b), values shown are means +/− SEM, and in each case the
results shown are representative of three independent experiments.
Parent lines used in crosses indicated in key. Differences in climbing
index between genotypes were analysed by ANOVA (n = 30).
Lifespans were analysed by Kaplan Meier statistics (n = 90). See also
Additional file 1: Figure S7
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was absent when Drosophila expressing only Htt-Q72-
EGFP were raised on food supplemented with DTT
(Fig. 6c&d). Similarly, when Drosophila co-expressing
R406W tau and CLU were reared on food supple-
mented with 5 mM DTT to induce ER stress (but not
otherwise), there was a rescue of the rough eye pheno-
type (Fig. 6e) and a concomitant reduction in the quan-
tity of phosphorylated, insoluble R406W tau deposits
detected by SDS PAGE (Fig. 6f ). These data indicate
that CLU-mediated protection against the aggregation
and neurotoxicity of Htt-Q72 and R406W tau is com-
pletely dependent upon ER stress (Fig. 6c-f ).
Discussion
Although the precise pathway of release remains to be
determined, multiple studies now strongly suggest that
ER stress triggers the release of post-translationally
modified CLU from the ER to the cytoplasm [15–17]
(see also Additional file 1: Figure S1). This may well ex-
plain the many previous reports that, under a variety of
disease conditions, CLU occurs in cellular locations out-
side the secretory system, including the co-localization
of CLU with intracellular tau tangles in Alzheimer’s dis-
ease [44], α-synuclein rich Lewy bodies in Parkinson’s dis-
ease [45], and inclusion bodies in myofibrillar myopathies
Fig. 6 CLU provides ER stress-dependent protection against proteotoxicity. a Light and scanning electron micrographs demonstrating the effects
of expression of TDP-43, Htt-Q128 and tau R406W (+/− CLU) in the photoreceptor neurons of adult Drosophila. Light micrographs (left) of Drosophila
eyes collected using a 7X objective, electron micrographs (right) taken at 200X magnification. For Htt-Q128 and tau R406W, the images shown on the
right are optical zooms of the corresponding images on the left. All images are representative of many experiments. b Western blot of whole non-
transgenic Drosophila head lysates prepared from Drosophila fed normal food (−DTT) or food supplemented with DTT (+DTT); detection
of XBP1-EGFP indicates activation of the UPR (β-actin was used as a loading control). c Fluorescence micrograph images (collected using
a 7X objective) of eyes on Drosophila fed with food +/− DTT (or not), and expressing Htt-Q72-EGFP +/− CLU. d Quantification of the
number of individual EGFP accumulations per eye, using images such as those shown in (c) and ImageJ (particle analyser program);
**p = 0.0037, n = 9, Student’s t-test. Results shown are representative of several independent experiments. e Light micrographs (collected
using a 7X objective) showing the eye phenotype in adult Drosophila fed normal food (−DTT) or food supplemented with DTT (+DTT)
resulting from expression of R406W tau +/− CLU in the photoreceptor neurons. f Western blot of Drosophila head homogenates prepared
from non-transgenic (Non-TG) Drosophila or Drosophila described in (e)
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[46]. It has also been reported that in response to chemo-
therapeutic drug treatment, CLU relocates to mitochon-
dria and interacts with Bax to inhibit apoptosis [47].
There is abundant evidence from transgenic mouse
models of ALS, neuropathological post mortem studies,
and genetic studies that ER stress is a significant compo-
nent in ALS pathology [48, 49]. While certainly not in
themselves definitive, the results of our own immunohis-
tochemical analyses of ALS patient spinal cord tissues are
consistent with CLU also being released from the ER in
ALS affected neurons (Additional file 1: Figure S2).
Furthermore, the inappropriate mislocalization and ac-
cumulation of TDP-43 in cytoplasmic inclusions is a
unifying pathology in frontotemporal dementia (FTD)
and familial and sporadic ALS cases. It is seen, with the
exception of cases resulting from SOD1 mutations [50],
in most post-mortem cases of FTD and ALS [51], and
correlates well with synaptic pathology and cognitive
deficits [52]. Thus, a therapeutic strategy that protects
against TDP-43 proteotoxicity could provide benefits in
most cases of ALS. Therefore, in the present study we
used a variety of complementary approaches, including in
vitro, cell and whole animal models, to evaluate whether
the unusually potent and multifunctional chaperone CLU
can affect the aggregation, cytoplasmic mislocalization and
proteotoxicity of TDP-43.
We showed using both a C-terminal peptide corre-
sponding to the most aggregation-prone region of TDP-
43, and full length in vitro translated TDP-43-tGFP, that
CLU potently inhibits the in vitro aggregation of TDP-
43 and maintains it in a soluble form (Fig. 2). These re-
sults strongly suggest that CLU can directly interact with
TDP-43, as there is no known mechanism by which a
chaperone can inhibit protein aggregation without dir-
ectly interacting with the client protein. The ability of
CLU to inhibit the aggregation of the TDP-43286-331 pep-
tide even at molar ratios of CLU:peptide as low as
1:1000 could arise from the fact that only a very small
fraction of the soluble peptide molecules may be in a
misfolded conformation at any one time, enabling CLU
to interact specifically with these species to stabilize
them and prevent them acting as aggregation nuclei
[10]. We also showed using three different transfected
cell models (N2a, SH-SY5Y and U251), that during ER
stress, but not otherwise, CLU co-localized with cyto-
plasmic TDP-43-GFP inclusions (Fig. 1, Additional file 1:
Figure S3). The treatments used to induce ER stress in
the cell models (MG132, Tg and A23187) have been
widely used in other studies [15–18] and we confirmed
that even an 18 h exposure of N2a cells to 10 uM
MG132 had negligible effects on cell viability (Additional
file 1: Figure S4). In N2a cells, we showed that over-
expression of CLU specifically and significantly reduced
the numbers of inclusions within these cells (Fig. 2c).
Co-immunoprecipitation analyses demonstrated that
CLU can physically associate with TDP-43CTF-GFP in
N2a cell lysates (Fig. 1b), suggesting that once in the
cytosol, CLU would be capable of forming stable com-
plexes with TDP-43.
In transgenic Drosophila we showed that overexpres-
sion of TDP-43 induced both ER stress and the retention
of CLU within both photoreceptor and motor neurons
(Fig. 3). Under these conditions, CLU was shown to co-
localize with TDP-43 first in the cytoplasm and then, at
later stages in development, in the nuclei of adult Dros-
ophila motor neurons, effectively restoring the normal
nuclear distribution of TDP-43 (Fig. 4). In this whole
animal model, the effects of enforced CLU expression
were to generate a dramatic recovery of the loss of loco-
motor activity associated with TDP-43 proteotoxicity,
and a significant extension of lifespan (Fig. 5). These
striking effects are specific to CLU expression as we
showed that the co-expression of GFP in TDP-43-
expressing Drosophila did not alter either the level of
TDP-43 expression or the median survival (Additional
file 1: Figure S7). Finally, we showed that enforced CLU
expression could also protect against the proteotoxicity
of Htt-Q72 and R406W tau expressed in Drosophila
photoreceptor neurons, but only when ER stress was
chemically induced (Fig. 6).
In both the neuronal cell and Drosophila models stud-
ied here, ER stress was a consistent requirement for
CLU to provide protection against protein mislocaliza-
tion and toxicity. We cannot exclude the suggestion that
over-expression of CLU might act to reduce the levels of
experimentally induced ER stress, and this might ac-
count in part for the protective effect of CLU expression.
However, even if this were correct, our results in trans-
genic Drosophila strongly suggest that this is not the
only mechanism by which CLU over-expression can
protect against the cytoplasmic accumulation of toxic
proteins. Notably, the level of cytoplasmic accumula-
tion/toxicity of Htt-Q72/R406W tau expressed in cells of
the Drosophila eye is unaffected by either DTT treat-
ment alone or CLU co-expression alone, but is signifi-
cantly reduced only when the two conditions are
combined (Fig. 6). Furthermore, in transfected N2a cells,
we only measure the release of CLU to the cytosol fol-
lowing treatments to induce ER stress, again strongly
suggesting that CLU over-expression does not ablate the
induction of ER stress. All our findings are consistent
with a model in which ER stress induces release of CLU
to the cytosol where it exerts effects that act to reduce
net TDP-43 accumulation. There are a several putative
mechanisms by which cytosolic CLU could exert the ob-
served effects on TDP-43 mislocalization, aggregation,
toxicity and clearance. These include (i) the well charac-
terized chaperone activity of CLU [11, 12, 53] allowing it
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to directly interact with TDP-43 to form stable, soluble
complexes, thereby inhibiting its further aggregation to
form cytoplasmic inclusions, (ii) CLU may interact with
misfolded species of TDP-43 to neutralize their toxicity,
as is the case in its interactions with other toxic protein
oligomers [12, 54, 55], and (iii) CLU, which is ubiquiti-
nated once in the cytosol [15], may direct soluble CLU-
TDP-43 complexes towards the proteasome or autophagy
for degradation. Both the proteasome and autophagy are
known to act to clear TDP-43 inclusions [56] and there is
a growing body of evidence implicating CLU as a substrate
of both these major cellular degradative pathways and a
control element of autophagy [15, 19–22]. It is also inter-
esting to note in this context that Cha-Molstad et al. have
recently reported that in response to MG132-mediated in-
hibition of the proteasome, or cytosolic foreign DNA, the
ER-resident chaperone BiP is released to the cytosol [18].
We speculate therefore that the release of CLU to the
cytosol might form a part of a larger strategy in which
multiple chaperones are released from the ER to the cyto-
sol to defend the cell against intracellular stresses.
An important aspect of motor neurons is that they
have a very limited heat shock response owing to their
impaired ability to activate the key molecular heat shock
response molecule, HSF1 [57]. This results in a high
threshold for induction of the heat shock response in
motor neurons conferring an element of vulnerability.
The results presented in this study provide a clear dem-
onstration in a whole organism model that during ALS
disease-relevant conditions the enforced expression of
CLU provides significant protection against the TDP-43-
mediated proteotoxicity underpinning pathology, to
substantially enhance motor neuron survival, reduce
locomotor deficits and extend lifespan. We have shown
previously that constitutively intracellular chaperones
are able to rescue TDP-43 associated neurotoxicity [14],
however this is the first instance, to our knowledge,
where a normally secreted chaperone can exert similar
protective effects.
In protein misfolding diseases such as ALS and Alzheimer’s
disease (AD) there are multiple proteins misfolding in both
the intra- and extracellular environments. For example,
pathological, extracellular amyloid beta accumulation is often
seen in post-mortem ALS and AD cases exhibiting intracellu-
lar accumulation of TDP-43 or tau [58]. It appears feasible
that CLU can combat protein misfolding in both the
intra- and extracellular compartments and may alter its
subcellular localization dependent upon the environ-
mental stress. Previous studies attempting to harness
the therapeutic benefits of chaperones in protein misfold-
ing diseases have used Hsp90 inhibitors, such as 17-AAG,
which can upregulate small heat shock proteins in the
intracellular compartment. 17-AAG can rescue the neuro-
toxicity associated with the pathological accumulation of
TDP-43, polyglutamine, alpha synuclein, mutant androgen
receptor, tau and amyloid beta [59–63]. However, 17-
AAG also upregulates CLU expression [64], potentially
contributing to the neuroprotective effects afforded by the
therapeutic intervention in these models. Apart from
ALS, many other neurodegenerative diseases including
Alzheimer’s, Parkinson’s and Huntington’s diseases, also
feature ER stress associated with pathology [23]. There-
fore, it is conceivable that further studies investigating
temporal changes in CLU levels and localization associ-
ated with pathologies could reveal new avenues for de-
veloping therapeutic strategies to address currently
incurable and highly devastating diseases.
Conclusions
The results presented in this study demonstrate in a
whole organism model that during ALS disease-relevant
conditions, enforced CLU expression significantly pro-
tects against TDP-43-mediated proteotoxicity to sub-
stantially enhance motor neuron survival, reduce
locomotor deficits and extend lifespan. This is the first
instance, to our knowledge, where a normally secreted
chaperone has been shown to exert such protective ef-
fects in the intracellular context.
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